Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Astrazeneca
    Topic: 
    targereted therapy
    Date added: 
    11/16/2022
    Relationship end date: 
    11/20/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Pfizer
    Topic: 
    Advisory board
    Date added: 
    11/16/2022
    Relationship end date: 
    11/26/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    BMS
    Topic: 
    Advisory board
    Date added: 
    11/16/2022
    Relationship end date: 
    11/19/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    DSI
    Topic: 
    Advisory board
    Date added: 
    11/16/2022
    Relationship end date: 
    11/19/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Neogenomics
    Topic: 
    Advisory board
    Date added: 
    11/16/2022
    Relationship end date: 
    11/26/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Merck
    Topic: 
    advisory board
    Date added: 
    11/16/2022
    Relationship end date: 
    11/26/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    BMS
    Topic: 
    CME content
    Date added: 
    11/16/2022
    Relationship end date: 
    11/13/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Janssen
    Topic: 
    CME content
    Date added: 
    11/16/2022
    Relationship end date: 
    11/17/2025
Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology